1. Dick AD, Azim M, Forrester JV. Immunosuppressive therapy for chronic uveitis: optimizing therapy with steroids and cyclosporine A. Br J Ophthalmol. 1997; 81:1107–12.
2. De Vries J, Baarsma GS, Zaal MJ, et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol. 1990; 74:344–9.
Article
3. Kuk JH, Jung WJ, Jo GH, et al. Production of N-acetyl-beta-D- glucosamine from chitin by Aeromonas sp. GJ-18 crude enzyme. Appl Microbiol Biotechnol. 2005; 68:384–9.
4. Alvarez-Soria MA, Largo R, Calvo E, et al. Differential anticatabolic profile of glucosamine sulfate versus other anti- osteoarthritic drugs on human osteoarthritic chondrocytes and synovial fibroblasts in culture. Osteoarthritis Cartilage. 2005; 13:153.
5. Reginster JY, Bruyere O, Neuprez A. Current role of glucosamine in the treatment of osteoarthritis. Rheumatology. 2007; 46:731–35.
Article
6. Botting RM. Inhibitors of cyclooxygenases: mechanisms, selec-tivity and uses. J Physiol Pharmacol. 2006; 57:113–24.
7. Chen JT, Chen CH, Horng CT, et al. Glucosamine sulfate inhibits proinflammatory cytokine-induced ICAM-1 production in human conjunctival cells in vitro. J Ocular Pharmacol Ther. 2006; 22:402–16.
8. Chen JT, Liang JB, Chou CL, et al. Glucosamine sulfate inhibits TNF-α and IFN-γ induced production of ICAM-1 in human retinal pigment epithelial cells in vitro. Invest Ophthalmol Vis Sci. 2006; 47:664–72.
9. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of Uveitis Nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140:509–16.
10. Forrester JV, Mc Menamin PG. Immunopathogenic mechanisms in intraocular inflammation. Chem Immunol. 1999; 73:159–85.
Article
11. Forrester JV. Autoimmunity and autoimmune disease of the eye. Dev Ophthalmol. 1999; 30:167–86.
Article
12. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003; 110:255–8.
Article
13. Largo R, Alvasrez-Soria MA, Diez-Ortego I, et al. Glucosamine inhibits IL-1beta-induced NF kappa B activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2003; 11:290–8.
14. Wang XC, Jobin C, Allen JB, et al. Suppression of NF- kappaB dependent proinflammatory gene expression in human RPE cells by a proteasome inhibitor. Invest Ophthalmol Vis Sci. 1999; 40:477–86.
15. Platts KE, Benson MT, Rennie IG, et al. Cytokine modulation of adhesion molecule expression on human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1995; 36:2262–9.
16. Abraham c, Griffith J, Miller J. The dependence for leukocyte function-associated antigen-1/ICAM-1 interactions in T cell activation cannot be overcome by expression of high density TCR ligand. J Immunol. 1999; 162:4399–405.
17. Pham T, Cornea A, Blick KE, et al. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. Am J Med Sci. 2007; 333:333–9.
Article
18. Ossendza RA, Grandval P, Chinoune F, et al. Acute cholestatic hepatitis due to glucosamine forte. Gastroenterol Clin Biol. 2007; 31:449–50.